CervoMed Inc. (CRVO) stock
CRVONasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.45−0.05 (-3.33%)
Close on Nov 18, 2026Market cap $21.92MP/E –Yield –
CervoMed revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
CervoMed's revenue for the twelve months ending Jun 30, 2026 was $331.30K, down 95.7% year over year. For fiscal 2025 it was $4.01M, down 58.9% from the year before. The highest annual figure on record is $9.74M in fiscal 2024.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.01M | -58.9% |
| FY2024 | Dec 31, 2024 | $9.74M | +36.3% |
| FY2023 | Dec 31, 2023 | $7.14M | – |
| FY2022 | Dec 31, 2022 | $0 | -100.0% |
| FY2013 | Dec 31, 2013 | $71.67K | -80.9% |
| FY2012 | Dec 31, 2012 | $374.54K | -34.3% |
| FY2011 | Dec 31, 2011 | $570.48K | +1319.5% |
| FY2010 | Dec 31, 2010 | $40.19K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $0 | -100.0% |
| Q1 FY2026 | Mar 31, 2026 | $0 | -100.0% |
| Q4 FY2025 | Dec 31, 2025 | $8.73K | -99.6% |
| Q3 FY2025 | Sep 30, 2025 | $322.57K | -83.4% |
| Q2 FY2025 | Jun 30, 2025 | $1.76M | -46.6% |
| Q1 FY2025 | Mar 31, 2025 | $1.92M | -18.3% |
| Q4 FY2024 | Dec 31, 2024 | $2.16M | -13.2% |
| Q3 FY2024 | Sep 30, 2024 | $1.94M | +27.1% |
| Q2 FY2024 | Jun 30, 2024 | $3.29M | +91.2% |
| Q1 FY2024 | Mar 31, 2024 | $2.35M | +66.7% |
| Q4 FY2023 | Dec 31, 2023 | $2.49M | – |
| Q3 FY2023 | Sep 30, 2023 | $1.53M | – |
| Q2 FY2023 | Jun 30, 2023 | $1.72M | – |
| Q1 FY2023 | Mar 31, 2023 | $1.41M | – |
| Q4 FY2022 | Dec 31, 2022 | $0 | – |
| Q3 FY2022 | Sep 30, 2022 | $0 | – |
See a number that looks wrong?